Phagenesis Taps Chad Hoskins as CEO Following $42M Series D Raise
- Orsco Lifesciences AG
- Sep 4, 2024
- 1 min read
Manchester, UK — Sept. 5, 2024. Phagenesis has named Chad Hoskins as its new Chief Executive Officer, bolstering its growth trajectory following a successful $42 million Series D financing led by EQT Life Sciences and Sectoral Asset Management, with support from British Patient Capital, Northern Gritstone, and Aphelion. (Phagenesis)
Hoskins brings over two decades of leadership in MedTech commercialization—including roles as CEO of Axon Therapies, head of Commercial Strategy at Outset Medical (including its IPO), and divisional VP at Abbott. He holds degrees from Georgetown, Columbia, and Wharton. (Phagenesis)
Context for growth: Phagenyx®, the company’s pioneering neurostimulation device for treating dysphagia, has been cleared in both Europe and the U.S., offering stroke patients a non-surgical route to restoring swallowing function and reducing hospitalization burdens. (Phagenesis)
Governance note: Ørn R. Stuge, MD, MBA serves as Chairman of Phagenesis—providing deep medtech governance know-how that underpins the company’s expansion across Europe and the U.S.
ing the appointment and financing details (MassDevice)
Comments